(Q34560520)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

title

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

Luis López Lázaro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

5

J H Beijnen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

J M Rademaker-Lakhai

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

H Rosing

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

J H M Schellens

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

1 October 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

429-436

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16133794%20AND%20SRC:MED&resulttype=core&format=json

The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyU-l-nitrosourea (BCNU) in man and animals

6 January 2020

cites work

1 reference

12 December 2020

Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo.

1 reference

12 December 2020

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

1 reference

12 December 2020

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

1 reference

12 December 2020

Distribution and excretion studies of procarbazine in animals and man

1 reference

12 December 2020

A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours

1 reference

12 December 2020

Preclinical and clinical results with the natural marine product ET-743

1 reference

12 December 2020

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin

1 reference

12 December 2020

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

1 reference

12 December 2020

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

1 reference

12 December 2020

Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.

1 reference

12 December 2020

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

1 reference

12 December 2020

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.

1 reference

12 December 2020

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies

1 reference

12 December 2020

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

1 reference

12 December 2020

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

12 December 2020